SOHO State of the Art Updates and Next Questions | Choosing the Best Frontline BCR::ABL1 Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia—How to Define the Treatment Value?
Haddad FG et al. Clin Lymphoma Myeloma Leuk, October 2025 (epub ahead of print)
Link to full abstract